16.40

2.09% -0.35

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $16.40, with a volume of 832.64K. It is down -2.09% in the last 24 hours and up +24.71% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$16.75

Open:

$16.77

24h Volume:

832.64K

Relative Volume:

0.76

Market Cap:

$1.00B

Revenue:

$13.73M

Net Income/Loss:

$-114.48M

P/E Ratio:

-8.9043

EPS:

-1.8418

Net Cash Flow:

$-78.49M

1W Performance:

+5.53%

1M Performance:

+24.71%

6M Performance:

+15.82%

1Y Performance:

-35.96%

1-Day Range:

$15.97

$16.83

1-Week Range:

$15.22

$16.91

52-Week Range:

$12.12

$35.34

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

108

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	16.40	1.00B	13.73M	-114.48M	-78.49M	-1.8418
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Downgrade	Barclays	Overweight → Underweight
Apr-15-26	Downgrade	UBS	Buy → Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Overweight
Sep-10-25	Initiated	Stifel	Buy
Sep-10-25	Initiated	Truist	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-11-25	Initiated	Raymond James	Outperform
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Jul 11, 2026

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits

Jul 11, 2026

Jul 10, 2026

Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan

Jul 10, 2026

Jul 09, 2026

Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance

Jul 09, 2026

Jul 08, 2026

Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st

Jul 08, 2026

Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily

Jul 08, 2026

Jul 03, 2026

Janux Therapeutics Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises 6%Dividend Cut Risk - dars.gov.et

Jul 03, 2026

Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView

Jul 03, 2026

Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView

Jul 03, 2026

Jun 30, 2026

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey

Jun 28, 2026

Jun 27, 2026

Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo

Jun 25, 2026

Jun 24, 2026

Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India

Jun 24, 2026

Jun 23, 2026

Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia

Jun 23, 2026

Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks

Jun 23, 2026

Janux Therapeutics announces departure of chief medical officer - Investing.com

Jun 23, 2026

CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan

Jun 23, 2026

Jun 20, 2026

JANX Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Clinical ProgressAnalyst Coverage Count - dars.gov.et

Jun 20, 2026

Jun 19, 2026